Drug Trial Radar · NCT00134264
A Study Examining Torcetrapib/Atorvastatin And Atorvastatin Effects On Clinical CV Events In Patients With Heart Disease
Last checked: Nov 19, 2026Latest source record: Feb 3, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
15,067
Actual
Start
Jul 2004
Primary completion
Jun 2007
Study completion Jun 2007
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Aug 24, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 45 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To demonstrate if torcetrapib/atorvastatin can reduce the risk for major cardiovascular disease events, when compared to atorvastatin alone, in patients with coronary heart disease or risk equivalents
Conditions
- Coronary Disease
- Diabetes Mellitus
Interventions
torcetrapib/atorvastatinDrug
atorvastatinDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- The time to first occurrence of a major cardiovascular disease event
Locations
221 sites in 7 countries. Site status is shown where the registry gives one.
Pfizer Investigational Site
Alabaster, Alabama
Pfizer Investigational Site
Birmingham, Alabama
Pfizer Investigational Site
Gilbert, Arizona
Pfizer Investigational Site
Phoenix, Arizona
Pfizer Investigational Site
Tucson, Arizona
Pfizer Investigational Site
Fresno, California
Pfizer Investigational Site
Los Angeles, California
Pfizer Investigational Site
Modesto, California
Pfizer Investigational Site
San Diego, California
Pfizer Investigational Site
Santa Rosa, California
Pfizer Investigational Site
Tustin, California
Pfizer Investigational Site
Walnut Creek, California
Pfizer Investigational Site
Denver, Colorado
Pfizer Investigational Site
Longmont, Colorado
Pfizer Investigational Site
Guilford, Connecticut
Pfizer Investigational Site
Hartford, Connecticut
Pfizer Investigational Site
Washington D.C., District of Columbia
Pfizer Investigational Site
Clearwater, Florida
Pfizer Investigational Site
Coral Gables, Florida
Pfizer Investigational Site
Fort Meyers, Florida
Pfizer Investigational Site
Jacksonville, Florida
Pfizer Investigational Site
Jacksonville Beach, Florida
Pfizer Investigational Site
Lakeland, Florida
Pfizer Investigational Site
Orlando, Florida
Pfizer Investigational Site
Pensacola, Florida
Pfizer Investigational Site
Port Charlotte, Florida
Pfizer Investigational Site
Sarasota, Florida
Pfizer Investigational Site
West Palm Beach, Florida
Pfizer Investigational Site
Atlanta, Georgia
Pfizer Investigational Site
Aurora, Illinois
Pfizer Investigational Site
Blue Island, Illinois
Pfizer Investigational Site
Chicago, Illinois
Pfizer Investigational Site
Evansville, Indiana
Pfizer Investigational Site
Fort Wayne, Indiana
Pfizer Investigational Site
Davenport, Iowa
Pfizer Investigational Site
Des Moines, Iowa
Pfizer Investigational Site
Iowa City, Iowa
Pfizer Investigational Site
Wichita, Kansas
Pfizer Investigational Site
Witchita, Kansas
Pfizer Investigational Site
Louisville, Kentucky
Showing 40 of 221 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.